Variation in causes of death in patients with non-small cell lung cancer according to stage and time since diagnosis
- PMID: 25672893
- DOI: 10.1093/annonc/mdv061
Variation in causes of death in patients with non-small cell lung cancer according to stage and time since diagnosis
Abstract
Background: Many patients with non-small cell lung cancer (NSCLC) die within the first few years of diagnosis, and considerable excess mortality remains even after 5 years. We investigated the death rate and the distribution of causes of death for NSCLC patients by age and stage at diagnosis during long-term follow-up.
Patients and methods: All 72 021 patients aged 45-89 years diagnosed with stage I-III NSCLC between 1989 and 2008 in the Netherlands and who died up till 2011 were derived from the Netherlands Cancer Registry and linked with the database of Statistics Netherlands for underlying causes of death. Mortality ratios and proportional distribution of causes of death were calculated during 5 time periods after diagnosis of NSCLC (up to 15 years).
Results: Median follow-up was 9.6 years (range: 0-23 years). Lung cancer was the predominant cause of death in the first 6 years after diagnosis (being 80%-85% and ∼90% up to 3 years for localized and locally advanced disease, respectively, and ∼60%-75% and ∼75%-85% during years 4-6 for both stage groups, respectively). Thereafter, lung cancer as cause of death proportionally decreased with time since diagnosis, but remained over 30%. Hence, cardiovascular diseases and chronic obstructive pulmonary diseases (COPD) became more important causes of death, especially for patients aged >60 years at diagnosis (up to 34% for cardiovascular diseases and up to 19% for COPD).
Conclusions: With time, the relative contribution of cardiovascular and COPD causes of death increased, although the absolute contribution of lung cancer remained high in non-metastatic NSCLC. Therefore, managing morbidity of these diseases remains relevant.
Keywords: causes of death; conditional survival; excess mortality; long-term; non-small cell lung cancer.
© The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Similar articles
-
Risk of mortality from cardiovascular and respiratory causes in patients with chronic obstructive pulmonary disease submitted to follow-up after lung resection for non-small cell lung cancer.J Cardiovasc Surg (Torino). 2007 Jun;48(3):375-83. J Cardiovasc Surg (Torino). 2007. PMID: 17505444
-
Pulmonologist involvement, stage-specific treatment, and survival in adults with non-small cell lung cancer and chronic obstructive pulmonary disease.Ann Am Thorac Soc. 2015 May;12(5):742-51. doi: 10.1513/AnnalsATS.201406-230OC. Ann Am Thorac Soc. 2015. PMID: 25760983 Free PMC article.
-
Comparison of survival of chronic obstructive pulmonary disease patients with or without a localized non-small cell lung cancer.Lung Cancer. 2016 Oct;100:90-95. doi: 10.1016/j.lungcan.2016.08.006. Epub 2016 Aug 11. Lung Cancer. 2016. PMID: 27597286
-
Cause-specific death after surgical resection for early-stage non-small-cell lung cancer.Eur J Cardiothorac Surg. 2018 Jan 1;53(1):221-227. doi: 10.1093/ejcts/ezx274. Eur J Cardiothorac Surg. 2018. PMID: 28950311
-
The prognosis of non-small cell lung cancer combined with chronic obstructive pulmonary disease: A systematic review and meta-analysis.Clin Respir J. 2020 Apr;14(4):389-396. doi: 10.1111/crj.13144. Epub 2020 Feb 3. Clin Respir J. 2020. PMID: 31905419 Free PMC article.
Cited by
-
Endostar acts as a pneumonitis protectant in patients with locally advanced non-small cell lung cancer receiving concurrent chemoradiotherapy.BMC Cancer. 2024 Feb 23;24(1):257. doi: 10.1186/s12885-024-12001-6. BMC Cancer. 2024. PMID: 38395838 Free PMC article.
-
Long-term mortality among women with epithelial ovarian cancer.Gynecol Oncol. 2015 Aug;138(2):421-8. doi: 10.1016/j.ygyno.2015.06.005. Epub 2015 Jun 5. Gynecol Oncol. 2015. PMID: 26050923 Free PMC article.
-
Long-term survival of patients with central or > 7 cm T4 N0/1 M0 non-small-cell lung cancer treated with definitive concurrent radiochemotherapy in comparison to trimodality treatment.Radiat Oncol. 2022 Jul 16;17(1):126. doi: 10.1186/s13014-022-02080-9. Radiat Oncol. 2022. PMID: 35842712 Free PMC article.
-
Doxycycline inhibits electric field-induced migration of non-small cell lung cancer (NSCLC) cells.Sci Rep. 2019 May 30;9(1):8094. doi: 10.1038/s41598-019-44505-8. Sci Rep. 2019. PMID: 31147570 Free PMC article.
-
Impact of prior cancer history on the overall survival of younger patients with lung cancer.ESMO Open. 2020 Feb;5(1):e000608. doi: 10.1136/esmoopen-2019-000608. ESMO Open. 2020. PMID: 32054633 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical